HMH Maestro
  • Action Center
  • Topics
  • On-Call Schedules
  • CME
  • Helpful Tools
Open main menu
  • Action Center
  • Topics
  • On-Call Schedules
  • CME
  • Helpful Tools
  • Topics
  • Hospitals and Locations
  • JFK University Medical Center Offers PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer

JFK University Medical Center Offers PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer

Published:
January 25, 2023

What You Need to Know

JFK University Medical Center now offers PYLARIFY® (piflufolastat F 18) injection, a prostate cancer imaging test.

The injection is given to a patient through a vein in the arm. That injection binds to prostate cancer cells sending a radio signal which, during a PET scan, shows where the drug is gathering to indicate where the cancer is. A three dimensional picture of the inside of the body, enables doctors to see lymph nodes, bone, and soft tissue metastasis to determine the presence or absence of recurrent and/or metastatic prostate cancer. 

PYLARIFY is indicated for patients with suspected prostate cancer metastasis who are potentially curable via surgery or other therapy. Patients are considered for PSMA if a blood test shows high levels of PSA. If there is a high PSA level then a doctor may order the PSMA test. It is also indicated for patients with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.

  1. Clinical Alerts
  2. Featured Physicians
  3. Featured Specialties
  4. HMH Partners Updates
  5. Hospitals and Locations
  6. IT Alerts
  7. Leadership Announcements
  8. Legal and Regulatory
  9. Payor Updates
  10. Physician Tips
  11. Quality and Safety
  • Topics
  • Hospitals and Locations
  • JFK University Medical Center Offers PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer

About HMH Maestro

  • Accessibility Statement
  • Careers

Information

  • Visitors/Guests
  • Patients

Privacy Policy|Terms & Conditions
© 2026
Hackensack Meridian Health, Inc.